Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  aprepitant
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-21 of 21 for your search:
Start Over
AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-00055-18, NCT00415103
Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GEICAM/2009-02, 2010-022689-29, NCT01298193
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
Phase: Phase IV
Type: Supportive care
Status: Closed
Age: 19 and over
Sponsor: Other
Protocol IDs: 2011348-01H, NCT01913990
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000544841, U10CA037420, URCC-U1105, URCC-04-02, U1105, NCT00475085
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: QL05-37, NCT00572572
ONO-7436 Phase II Study in Japan
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ONO-7436-01, NCT00212602
Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: INST 3204C, NCT00250744
Multi-day Doses in Prevention of Nausea and Emesis
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 10862, KUMC-10862, MGI-KUMC-10862, NCT00631930, NCT00600353
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0615, NCT00954941
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000503649, OHSU-SOL-06006-LM, OHSU-IRB-2302, 2302, NCT00381862
Emend for Multiple-day Emetogenic Chemotherapy
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0363, NCT00711555
Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2009-09-119, NCT01012336
Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer
Phase: Phase II
Type: Supportive care
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: RAD1.0, NCT01046461
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Phase: No phase specified
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000456201, P30CA022453, WSU-D-2797, WSU-0504001728, NCT00293384
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-1033, NCT00651755
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: LCCC 0514, P30CA016086, CDR0000600836, UNC-05-2917, UNC-GCRC-2411-ORC, UNC-LCCC-0514, NCT00719173
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
Phase: No phase specified
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000445452, OHSU-HEM-03074-L, OHSU-1057, MERCK-OHSU-HEM-03074-L, NCT00248547
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
Phase: No phase specified
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 03-1192, NCT00314743
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
Phase: No phase specified
Type: Supportive care
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000692516, GOG-0272, NCT01275664
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Phase: No phase specified
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU 02205, NCI-2009-01258, CCCWFU-EMEND, MERCK-CCCWFU-02205, NCT00398164, NCT01534637
Start Over